Dexamethasone Implants(EyePoint Pharma)

Tier C — Watch / trade

Eyepoint Pharmaceuticals Inc

Originator

2018

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GR

Brand：DEXYCU, Dexycu Kit

Indications (approved)：Postoperative inflammation

Regional status

Withdrawn

China

Approved

2026-06-30

Japan

Factories producing this API3

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

3 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Dexamethasone Implants(EyePoint Pharma)?

Approved indications include: Postoperative inflammation.

When does the Dexamethasone Implants(EyePoint Pharma) patent expire?

No public expiry year is available for Dexamethasone Implants(EyePoint Pharma) yet; this page updates once verified.

How do I get a quote for Dexamethasone Implants(EyePoint Pharma) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29